Group 1 - Eli Lilly and Company has signed a $1.12 billion agreement with Seamless Therapeutics to develop treatments for hearing loss using gene-editing technology [2][4] - The partnership allows Lilly access to proprietary technology for designing programmable recombinases that can make precise changes to DNA linked to hearing loss [3] - Lilly will manage the program from early preclinical stages to commercialization, with the agreement including upfront payments and milestone-related payments [4] Group 2 - This deal is part of Lilly's broader strategy to expand its pipeline of genetic medicines across various diseases, moving beyond its successful weight-loss and diabetes drugs [5] - In the previous year, Lilly invested $1.3 billion to acquire Verve Therapeutics, enhancing its focus on gene-editing therapies for heart-related conditions [5] - Eli Lilly is a global pharmaceutical firm engaged in the discovery, development, manufacturing, marketing, and sale of medicines worldwide [6]